Fundraising Fox
/Companies
Sign in

Nucleome

6 known investors

Find your way into Nucleome

Sign up to see every warm intro you have to Nucleome

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Nucleome team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.

AI & Machine LearningBiotechDeep Tech

Investors · 6

Oxford Science Enterpriseslisted by Oxford Science EnterprisesOxford · $63.5K – $31.8M

How we know: Oxford Science Enterprises's portfolio page · funding news · biospace.com · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us

British Patient CapitalreportedLondon

How we know: funding news · biospace.com · Not right? Tell us

JJDCreportedNew Brunswick · $500K – $5M

How we know: funding news · biospace.com · Not right? Tell us

Pfizer Venturesreported

How we know: funding news · biospace.com · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 10

Alterome Therapeutics, Inc.Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Noveome BiotherapeuticsNoveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.
MyomeMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.
CellanomeCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
OneOmeOneOme is a precision medicine company that provides pharmacogenomics testing and analytics to healthcare providers, helping them optimize medication selection based on patients' genetic profiles. Co-founded by Mayo Clinic, the company serves healthcare teams and institutions globally seeking to improve patient outcomes and reduce costs through personalized medication decisions.
nChroma BionChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.
SequomeSequome uses AI to engineer biological sequences for developing therapeutics, based on its sequence-to-function model called Gene Genie. The company has collaborated with large pharmaceutical firms and Google DeepMind in the drug discovery and biotechnology space.
FreenomeFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
EtiomeEtiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention. Founded in 2021 out of Flagship Pioneering's Preemptive Health and Medicine initiative, the biotech company focuses on treating or reversing disease before it advances to later stages.

Companies working in the same space as Nucleome.

In the news

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines - BioSpacebiospace.com · Oct 2022

Frequently asked questions

What does Nucleome do?
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
Who are Nucleome's investors?
Nucleome's investors include M Ventures, Oxford Science Enterprises, Pfizer Venture Investments, British Patient Capital, JJDC, Pfizer Ventures.